Rhythm Pharmaceuticals, Inc. RYTM
As ofNov 20, 2026, 1:14 PM EST
- YTD
- +5.06%
- 1 year
- +11.72%
5D -1.00 (-0.87%)
- Market cap
- 7.80B
- Revenue (ttm)
- 280.75M
- Profit margin
- -69.03%
- EPS (ttm)
- -2.91
- Shares out
- 69.33M
- Forward P/E
- -89.97
- YTD return
- +5.06%
- 1-year return
- +11.72%
- 50-day average
- 97.63
- 200-day average
- 97.36
- Volume
- 658.70K
- Avg volume
- 1.08M
- Open
- 115.46
- Previous close
- 116.80
- Day's range
- 112.38 – 117.01
- 52-week range
- 74.50 – 122.20
- Beta
- 2.13
- Analysts
- Strong Buy
- Price target
- 140.12 (+24.6%)
- Earnings date
- Feb 25, 2027
Key statistics
- Enterprise value
- 8.15B
- Price / sales
- 28.84
- Price / book
- 92.04
- Revenue growth
- 79.60%
- Free cash flow
- -17.76M
- Total cash
- 320.94M
- Total debt
- 106.18M
- Return on equity
- -77.96%
- Short % of float
- 16.98%
Fundamental scorecard
7 of 25 checks passed on RYTM’s reported financials
7of 25 checks passed
- Value 1 of 5
- Growth 2 of 5
- Profitability 1 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 112.00
- Target (mean)
- 140.12
- Target (high)
- 168.00
- Strong buy5
- Buy12
- Hold2
- Sell0
- Strong sell0
Next earnings
Feb 25, 2027
Expected Feb 25, 2027. Consensus EPS estimate -3.20.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 25, 2027 | Dec 30, 2026 | -2.84 | — | — | — |
| Nov 3, 2026 | Sep 30, 2026 | -0.70968 | -0.61 | +0.10 | +14.05% |
| Aug 4, 2026 | Jun 30, 2026 | -0.80721 | -0.73 | +0.08 | +9.57% |
| May 5, 2026 | Mar 31, 2026 | -0.86 | -0.83 | +0.03 | +3.49% |
| Feb 26, 2026 | Dec 31, 2025 | -0.79 | -0.73 | +0.06 | +7.59% |
| Nov 4, 2025 | Sep 30, 2025 | -0.72 | -0.82 | -0.10 | -13.89% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 6, 2026 | JP Morgan | main | Overweight | Overweight |
| Nov 5, 2026 | Guggenheim | main | Buy | Buy |
| Nov 4, 2026 | Citizens | main | Market Outperform | Market Outperform |
| Nov 3, 2026 | Needham | main | Buy | Buy |
| Oct 16, 2026 | William Blair | init | — | Outperform |
| Oct 15, 2026 | JP Morgan | main | Overweight | Overweight |
About Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, pro-opiomelanocortin (POMC) and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency obesity; and in phase 2 clinical trails for the treatment of Prader-Willi syndrome and MC4R deficiency. The company is also developing bivamelagon, an investigational oral small molecule MC4R agonist that is in phase 2 clinical trial for the treatment of MC4R pathway diseases; and RM-718, a next generation MC4R peptide agonist that is in phase 1 clinical trial for the treatment of hypothalamic obesity. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- rhythmtx.com
News
Citizens Maintains Market Outperform on Rhythm Pharmaceuticals, Lowers Price Target to $160
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Stock Has Consensus Target Price of $142.00
Rhythm Pharmaceuticals Shares See Volume; Traders Circulate M&A Rumors At $150/Share
Rhythm Pharmaceuticals Says Rare Obesity Drug Delivers Sustained Two-Year BMI Reductions
Rhythm Pharmaceuticals Says Rare Obesity Drug Delivers Sustained Two-Year BMI Reductions
Rhythm Pharmaceuticals Announces Presentation of New Data at ObesityWeek® 2026 Guggenheim Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $147
Citizens Maintains Market Outperform on Rhythm Pharmaceuticals, Raises Price Target to $166
Rhythm Pharmaceuticals Receives Positive Guidance For IMCIVREE From National Institute For Health And Care Excellence To Add Adults With Bardet-Biedl Syndrome
Needham Maintains Buy on Rhythm Pharmaceuticals, Lowers Price Target to $114
Your note
Sign in to keep a note on RYTM — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CRAMER PAMELA J. | Officer | Conversion of Exercise of derivative security | Jan 29, 2026 | 29,376 |
| GOOD JENNIFER L | Director | Conversion of Exercise of derivative security | Jun 22, 2026 | 11,712 |
| JEAN CHRISTOPHE R | Director | Conversion of Exercise of derivative security | Nov 16, 2026 | 11,712 |
| MATHERS EDWARD T. | Director | Conversion of Exercise of derivative security | Jun 17, 2025 | 12,771 |
| MAZABRAUD YANN | Officer | Conversion of Exercise of derivative security | Aug 11, 2026 | 55,655 |
| MCGIRR DAVID W J | Director | Conversion of Exercise of derivative security | Jun 22, 2026 | 11,712 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RA Capital Management, L.P. | 9.62% | 6,666,837 | 778.69M | Sep 29, 2026 |
| Blackrock Inc. | 8.62% | 5,975,285 | 697.91M | Sep 29, 2026 |
| Baker Bros. Advisors, LP | 8.08% | 5,604,483 | 654.60M | Sep 29, 2026 |
| JPMORGAN CHASE & CO | 5.13% | 3,558,229 | 415.60M | Sep 29, 2026 |
| Vanguard Portfolio Management LLC | 4.54% | 3,148,914 | 367.79M | Sep 29, 2026 |
| Primecap Management Company | 4.42% | 3,064,317 | 357.91M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.14% | 2,176,750 | 254.24M | Jun 29, 2026 |
| PRIMECAP Odyssey Funds-PRIMECAP Odyssey Aggressive Growth Fund | 2.79% | 1,935,739 | 226.09M | Sep 29, 2026 |
| SmallCap World Fund Inc | 2.55% | 1,769,519 | 206.68M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.27% | 1,572,293 | 183.64M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.16% | 1,496,330 | 174.77M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.71% | 1,184,359 | 138.33M | Sep 29, 2026 |
